Aktuell in Longevity

Semaglutide and tirzepatide redefining metabolic medicine; 92% of doctors now using for cardiovascular protection and inflammation reduction beyond weight loss.

Advanced biological age biomarkers at forefront of 2026 longevity trends, distinguishing biological from chronological age with growing clinical adoption.

Most-watched longevity molecule now supported by human trials showing improved immune resilience and cardiac function in older adults.

Life Biosciences initiating ER-100 trials for optic neuropathies in Q1 2026, rapidly advancing this ambitious anti-aging approach toward human trials.

Dasatinib + quercetin combination showing reduced senescence markers and improved immune function in aged populations across expanding human trials.

Focus shifting from simply topping off NAD+ levels to stopping the metabolic leak; NMN and NR research accelerating in human trials.

Direct-to-consumer epigenetic age testing exploding in 2026 as accessible tool for tracking longevity intervention efficacy in real time.

Suppress pro-inflammatory SASP secretions of senescent cells without killing them, offering a complementary approach to senolytics with a growing research base.

Natural compound improving mitochondrial function, morphology, and proteostasis gaining significant research and consumer interest in 2025-2026.

Human trials demonstrate boosts in attention, processing speed, executive function, and partial reversal of two key biological aging markers.

Empagliflozin and dapagliflozin showing multi-organ protective effects beyond diabetes, increasingly repurposed in longevity and cardiovascular protocols.

Enhances autophagy and improves immune function and vaccine responses; trending as a natural polyamine often stacked with rapamycin in longevity protocols.

TAME trial outcomes anticipated as landmark validation of metformin as a bona fide longevity drug targeting nutrient-sensing mechanisms.

Mitochondrial multitasker acting as backup electron carrier to boost ATP production and reduce oxidative stress, trending as a cellular repair biohack.

Apolipoprotein B increasingly tracked as the gold-standard lipid biomarker for cardiovascular risk in longevity medicine, displacing LDL-C.

Therapeutic plasma exchange reducing pro-aging plasma factors; gaining clinical traction following Conboy lab findings on heterochronic parabiosis mechanisms.

Extracellular vesicles used for tissue regeneration and inflammation reduction gaining traction in clinical regenerative longevity treatments.

Identified as a natural compound mediating multiple hallmarks of aging; landmark Nature study showing taurine decline with age drives supplementation interest.

Bioactive peptides supporting metabolism, hormone balance, and tissue regeneration increasingly stacked in personalized longevity protocols.

Testosterone, estrogen, and DHEA optimization as key components of the rebuilding phase in personalized longevity strategies, especially for women.

TCA cycle intermediate targeting nutrient-sensing and aging pathways; synergistic with other longevity compounds in stacked protocols.

Mesenchymal and other stem cell therapies leveraged for tissue regeneration in the regeneration phase of personalized longevity approaches.

Plant-derived flavonoid emerging as an accessible senolytic agent with accumulating human trial data on senescent cell clearance and healthspan.

Addressing unique female aging processes including ovarian function decline, perimenopause, and menopause management as a 2026 longevity focus.

Anti-aging hormone declining with age, linked to kidney function and cognitive health; gaining renewed interest as a potential longevity therapeutic target.

Emerging blood-based biomarker for early Alzheimer's detection, increasingly integrated into longevity brain health protocols and cognitive aging panels.

Popular biohack for skin health and cellular energy production via mitochondrial photobiomodulation, exploding in DTC consumer markets in 2026.

ProLon and similar fasting mimicking diets gaining clinical validation for cellular regeneration, metabolic reset, and biological age reduction.

Thymic rejuvenation via growth hormone, DHEA, and metformin protocols showing immune system restoration; TRIIM trial data sustaining interest.

Apigenin, quercetin, and novel CD38 inhibitors protecting NAD+ from enzymatic degradation, increasingly paired with NMN in advanced longevity stacks.

Glycine and N-acetylcysteine combination restoring glutathione levels and mitochondrial function in aged adults; Baylor trial data sustaining research interest.

Evolocumab and alirocumab gaining traction in longevity cardiology alongside ApoB testing for aggressive LDL lowering and cardiovascular risk reduction.

Age-related somatic mutations in blood stem cells linked to cardiovascular disease and cancer; emerging as a key aging risk factor in longevity medicine.

Glycan-based biological age test measuring IgG glycosylation patterns as an inflammatory aging clock, gaining DTC traction in longevity testing markets.